2025 연구자 정보 (28 / 654)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Park, Youngsu (Park, Y) |
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Powles, Thomas (Powles, T) |
AER-4585-2022 Powles, Thomas |
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Rimawi, Mothaffar F. (Rimawi, MF) |
AAI-3520-2020 Rimawi, Mothaffar |
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Saura Manich, Cristina (Manich, CS) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Schneeweiss, Andreas (Schneeweiss, A) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Shetty, Jagdish (Shetty, J) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Shin, Hyunjae (Shin, H) |
제1저자 | Natl Canc Ctr, Ctr Liver & Pancreatobiliary Canc, Goyang, Gyeonggi Do, South Korea |
|
0000-0003-1023-8795 Shin, Hyunjae |
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | |
|
Sohn, Joohyuk (Sohn, J) |
제1저자 |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | |||
|
Song, Byeong Geun (Song, BG) |
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Toi, Masakazu (Toi, M) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Tolaney, Sara M. (Tolaney, SM) |
제1저자 |
AFZ-2612-2022 Tolaney, S |
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | |||
|
Van Der Heijden, Michiel Simon (Van Der Heijden, MS) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Vu, Toan Quang (Vu, TQ) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Wojtukiewicz, Marek Z. (Wojtukiewicz, MZ) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Wu, Yue (Wu, Y) |
Brii Biosci Beijing Co Ltd, Beijing, Peoples R China |
|
|
[JCR상위 1.7%] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn |
페이지 이동: